Previous 10 | Next 10 |
Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting Cash balance of $201.7 million as of December 31, 2022; runway rema...
WILMINGTON, Del., March 15, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in c...
WILMINGTON, Del., March 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Barclays Global Healthcare Conference in Miami, March 14 to 16, 2023. On M...
WILMINGTON, Del., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in three healthcare investment conferences in February. On Tuesday, February...
Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...
Prelude Therapeutics press release ( NASDAQ: PRLD ): Q3 GAAP EPS of -$0.63. Cash, cash equivalents, and marketable securities as of September 30, 2022, were $224.0 million. Prelude anticipates that its existing cash, cash equivalents and marketable securities will be suffi...
FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation CDK4/6 inhibitor) Company to reprioritize clinical pipeline and discontinue PRMT5 program for internal development Strong cash, cash equivalents and marketable...
Prelude Therapeutics ( NASDAQ: PRLD ), an oncology-focused biotech, announced Tuesday that the FDA cleared its Investigational New Drug Application (IND) for PRT3789 allowing the company to start a Phase 1 trial for the antitumor agent. A protein degrader targeted at SMARC...
WILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and Drug Administration, (FDA) cleared the company to proceed with a Phase 1 study under its In...
Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
News, Short Squeeze, Breakout and More Instantly...
Prelude Therapeutics Incorporated Company Name:
PRLD Stock Symbol:
NASDAQ Market:
Prelude Therapeutics Incorporated Website:
2024-07-27 22:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 07:00:07 ET Peter Lawson from Barclays issued a price target of $3.00 for PRLD on 2024-06-20 05:33:00. The adjusted price target was set to $3.00. At the time of the announcement, PRLD was trading at $3.87. The overall price target consensus is at $10.67 with ...
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. Jefferies Global Healthcare Conference 2...